<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes, presentation, and evaluation of sellar masses</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes, presentation, and evaluation of sellar masses</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes, presentation, and evaluation of sellar masses</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sellar masses typically present in one or more ways:</p><p class="bulletIndent1"><span class="glyph">●</span>With neurologic symptoms, such as visual impairment, diplopia, or headache</p><p class="bulletIndent1"><span class="glyph">●</span>As an incidental finding on magnetic resonance imaging (MRI) or computed tomographic (CT) scanning performed for some other reason</p><p class="bulletIndent1"><span class="glyph">●</span>With hormonal abnormalities</p><p></p><p>This topic will review the causes, clinical manifestations, and evaluation of sellar masses. The clinical presentation and management of individual pituitary tumors, pituitary incidentalomas, and hypopituitarism are discussed separately. (See  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia"</a> and  <a class="medical medical_review" href="/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas"</a> and  <a class="medical medical_review" href="/d/html/6642.html" rel="external">"Pituitary incidentalomas"</a> and  <a class="medical medical_review" href="/d/html/6637.html" rel="external">"Clinical manifestations of hypopituitarism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CAUSES</span><span class="headingEndMark"> — </span>Pituitary adenomas are the most common cause of sellar masses from the third decade on, accounting for up to 10 percent of all intracranial neoplasms [<a href="#rid1">1-3</a>]. Other disorders, which are often difficult to distinguish from pituitary adenomas by imaging, include physiologic enlargement of the pituitary and benign and malignant tumors (<a class="graphic graphic_table graphicRef68108" href="/d/graphic/68108.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H3"><span class="h2">Pituitary adenomas</span><span class="headingEndMark"> — </span>Pituitary adenomas are benign tumors of the anterior pituitary, but they are true neoplasms, as shown by clonality studies [<a href="#rid4">4,5</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Incidence and prevalence</span><span class="headingEndMark"> — </span>There are few population studies of the incidence and prevalence of pituitary adenomas. However, a population-based study in Northern Finland, where all patients within a health care district are referred to a predetermined medical center, found the following standardized <strong>incidence</strong> rates per 100,000 (cases diagnosed between 1992 and 2007) [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>All pituitary adenomas – 4.0</p><p class="bulletIndent1"><span class="glyph">●</span>Lactotroph adenomas – 2.2</p><p class="bulletIndent1"><span class="glyph">●</span>Clinically nonfunctioning adenomas – 1.0</p><p class="bulletIndent1"><span class="glyph">●</span>Somatotroph adenomas – 0.34</p><p class="bulletIndent1"><span class="glyph">●</span>Corticotroph adenomas – 0.17</p><p></p><p>Past studies of pituitary adenomas in the population are thought to have underestimated their true prevalence. In a current report from a single community of over 80,000 inhabitants in England, the <strong>prevalence</strong> of pituitary adenomas per 100,000 was fourfold higher than previous estimates [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>All adenomas – 77.6</p><p class="bulletIndent1"><span class="glyph">●</span>Lactotroph adenomas – 44.4</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfunctioning adenomas – 22.2</p><p class="bulletIndent1"><span class="glyph">●</span>Somatotroph adenomas – 8.6</p><p class="bulletIndent1"><span class="glyph">●</span>Corticotroph adenomas – 1.2</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Genetics</span><span class="headingEndMark"> — </span>Classic oncogene mutations are rarely found in pituitary adenomas, but mutations in the following genes may play a role in the development of one or more types of pituitary adenomas:</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>MEN1</em></strong> – Loss-of-function mutations of this tumor suppressor gene appear to be responsible for the tumors that occur in the parathyroids, pancreatic islets, and pituitary glands of patients who have multiple endocrine neoplasia type 1 (MEN1) syndrome [<a href="#rid8">8</a>]. However, mutations in this gene do not appear to cause sporadic pituitary adenomas [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/2037.html" rel="external">"Multiple endocrine neoplasia type 1: Genetics"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gs-alpha</strong> – An activating mutation of the alpha subunit of the guanine nucleotide stimulatory protein (Gs-alpha) gene is found in approximately 40 percent of somatotroph adenomas [<a href="#rid10">10,11</a>]. These mutations result in constitutive activation of adenylyl cyclase, which may play a role in both cell division and excessive growth hormone secretion by these adenomas. (See  <a class="medical medical_review" href="/d/html/6633.html" rel="external">"Causes and clinical manifestations of acromegaly"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AIP</strong> – Mutations in the aryl hydrocarbon receptor-interacting protein (AIP) are associated with familial pituitary adenomas, usually somatotroph or somatomammotroph adenomas, that present in adolescence or early adulthood and are relatively aggressive [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Classification</span><span class="headingEndMark"> — </span>Adenomas are classified by size and the cell of origin. Lesions smaller than 1 cm are classified as microadenomas, and lesions larger than 1 cm are classified as macroadenomas. Adenomas can arise from any type of cell of the anterior pituitary and may result in increased secretion of the hormone(s) produced by that cell and/or decreased secretion of other hormones due to compression of other cell types [<a href="#rid13">13</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Gonadotroph adenomas usually present as clinically nonfunctioning sellar masses, but rarely cause symptoms due to hormonal hypersecretion. (See  <a class="medical medical_review" href="/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyrotroph adenomas may present as clinically nonfunctioning sellar masses that secrete only alpha or TSHB subunits or may cause hyperthyroidism due to increased secretion of intact thyroid-stimulating hormone (TSH). (See  <a class="medical medical_review" href="/d/html/7842.html" rel="external">"TSH-secreting pituitary adenomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Corticotroph adenomas usually cause Cushing disease, but a significant minority are "clinically silent" or totally silent. (See  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lactotroph adenomas usually cause hyperprolactinemia, which leads to hypogonadism in both females and males. (See  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Somatotroph adenomas typically cause acromegaly due to increased growth hormone secretion, but a significant minority are "clinically silent." (See  <a class="medical medical_review" href="/d/html/6633.html" rel="external">"Causes and clinical manifestations of acromegaly"</a> and  <a class="medical medical_review" href="/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lactotroph/somatotroph adenoma combinations that secrete both prolactin and growth hormone [<a href="#rid14">14</a>] are well recognized and cause the clinical syndromes of both hormones. Other mixed cell adenomas, sometimes called plurihormonal adenomas, can involve any combination of cells but are uncommon.</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Pituitary hyperplasia</span><span class="headingEndMark"> — </span>There are several recognized causes of hyperplasia of the pituitary. These may present as sellar masses and be misdiagnosed as pituitary adenomas:</p><p class="bulletIndent1"><span class="glyph">●</span>Lactotroph hyperplasia during pregnancy. (See  <a class="medical medical_review" href="/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyrotroph and gonadotroph hyperplasia due to longstanding primary hypothyroidism and primary hypogonadism, respectively [<a href="#rid15">15-19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Somatotroph hyperplasia due to ectopic secretion of growth hormone-releasing hormone, a rare condition [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Other benign tumors</span><span class="headingEndMark"> — </span>Several other benign tumors can occur in or near the sella, including craniopharyngiomas, meningiomas, and, less commonly, pituicytomas (<a class="graphic graphic_diagnosticimage graphicRef139625" href="/d/graphic/139625.html" rel="external">image 1</a>).</p><p class="headingAnchor" id="H9"><span class="h3">Craniopharyngioma</span><span class="headingEndMark"> — </span>Craniopharyngiomas are solid or mixed solid-cystic benign tumors that arise from remnants of Rathke's pouch along a line from the nasopharynx to the diencephalon. Most are either intrasellar or suprasellar (<a class="graphic graphic_diagnosticimage graphicRef139625" href="/d/graphic/139625.html" rel="external">image 1</a>).</p><p>Approximately 50 percent present clinically during childhood and adolescence, the other 50 percent present after age 20 years, some not until age 70 or 80 years. The major presenting symptoms are growth retardation in children and abnormal vision in adults. In addition, pituitary hormonal deficiencies, including arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus), are common. (See  <a class="medical medical_review" href="/d/html/5210.html" rel="external">"Craniopharyngioma"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Meningioma</span><span class="headingEndMark"> — </span>A meningioma is a usually benign tumor arising from the meninges anywhere within the head. Some arise near the sella, causing visual impairment and hormonal deficiencies. (See  <a class="medical medical_review" href="/d/html/5220.html" rel="external">"Epidemiology, pathology, clinical features, and diagnosis of meningioma"</a>.)</p><p class="headingAnchor" id="H691693"><span class="h3">Pituicytoma</span><span class="headingEndMark"> — </span>This is an uncommon, low-grade (World Health Organization [WHO] grade 1), indolent glioma arising from the pituicytes of the posterior pituitary. It presents as a sellar mass, which is usually mistaken for a pituitary adenoma, and has no known hormonal secretory function.</p><p class="headingAnchor" id="H11"><span class="h2">Malignant tumors</span><span class="headingEndMark"> — </span>Some malignant tumors arise within or near the sella, and others metastasize to this site.</p><p class="headingAnchor" id="H12"><span class="h3">Primary</span><span class="headingEndMark"> — </span>Malignancies that arise in the parasellar region include germ cell tumors, sarcomas, chordomas, and lymphomas. Pituitary carcinomas are rare [<a href="#rid21">21</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Germ cell tumors</strong> – Germ cell tumors, also called ectopic pinealomas, usually occur through the third decade of life and may present with headache, nausea, vomiting, and lethargy (from increased intracranial pressure in patients with pineal lesions); diplopia, hypopituitarism, or AVP-D (with suprasellar tumors); and paralysis of upward conjugate gaze (Parinaud syndrome). Imaging shows a mass in the third ventricle. Serum concentrations of human chorionic gonadotropin-beta (B-hCG) and/or alpha fetoprotein (AFP) may be increased. Although these lesions are highly malignant and metastasize readily, they are also highly radiosensitive. (See  <a class="medical medical_review" href="/d/html/5199.html" rel="external">"Intracranial germ cell tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chordomas</strong> – Chordomas usually are locally aggressive tumors that can metastasize. They often arise in the clivus and present with headaches, visual impairment, and anterior pituitary hormonal deficiencies. (See  <a class="medical medical_review" href="/d/html/5179.html" rel="external">"Chordoma and chondrosarcoma of the skull base"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary lymphoma</strong> – Primary central nervous system (CNS) lymphoma sometimes involves the pituitary and hypothalamus. A review of 13 patients with pituitary involvement noted neurologic symptoms (headaches and visual and oculomotor impairment) and/or deficiencies of anterior pituitary hormones and antidiuretic hormone [<a href="#rid22">22</a>]. Magnetic resonance imaging (MRI) shows a sellar mass with variable extrasellar extension. (See  <a class="medical medical_review" href="/d/html/4693.html" rel="external">"Primary central nervous system lymphoma: Clinical features, diagnosis, and extent of disease evaluation", section on 'Clinical features'</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h3">Metastatic disease</span><span class="headingEndMark"> — </span>Metastases to the hypothalamus and pituitary gland account for 1 to 2 percent of sellar masses [<a href="#rid1">1,23</a>]. They occur most commonly with breast cancer in women and lung cancer in men but can be seen with many other cancers [<a href="#rid24">24,25</a>]. Symptoms, which occur in approximately 7 percent of patients, include AVP-D, anterior pituitary dysfunction, visual field defects, retroorbital pain, and ophthalmoplegia [<a href="#rid23">23</a>]. Survival in 36 patients in one series averaged six months [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Cysts</span><span class="headingEndMark"> — </span>Several types of cysts can occur in the sellar and/or suprasellar area, including Rathke's cleft [<a href="#rid26">26,27</a>], arachnoid [<a href="#rid28">28</a>], and dermoid cysts. Rathke's cleft cysts, the most common, are benign cysts derived from remnants of Rathke's pouch, the same structure from which craniopharyngiomas arise (see  <a class="medical medical_review" href="/d/html/5210.html" rel="external">"Craniopharyngioma"</a>). The clinical characteristics of all are similar.</p><p>Most cysts are small and discovered incidentally by MRI. The MRI characteristics include a sellar and/or suprasellar, symmetrical, round or ovoid mass that enhances on either T1 or T2-weighted images but does not concentrate gadolinium. Larger cysts may cause headaches, visual impairment, and/or anterior pituitary hormonal deficiencies. Rarely, they bleed, causing apoplexy, or rupture, causing aseptic meningitis.</p><p>The natural history is variable. Of 75 patients with Rathke's cleft cysts followed for a median of 24 months, 57 percent had no change in size, 28 percent increased, and 15 percent decreased [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Abscess</span><span class="headingEndMark"> — </span>Pituitary abscesses, which are rare, can occur in a normal or diseased pituitary gland. In a series of 24 patients, 16 (67 percent) presented with symptoms and physical findings consistent with a pituitary mass, while only eight had features suggestive of infection (fever, leukocytosis, meningismus) [<a href="#rid29">29</a>]. Imaging studies, including computed tomography (CT) and MRI, were unable to distinguish between pituitary abscess and pituitary adenoma. As a result, most patients were diagnosed at the time of surgical exploration.</p><p class="headingAnchor" id="H16"><span class="h2">Arteriovenous fistula of the cavernous sinus</span><span class="headingEndMark"> — </span>Arteriovenous fistulae of the cavernous sinus can cause modest enlargement of the pituitary gland. Pituitary size returns toward baseline after the fistula is blocked [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Hypophysitis</span><span class="headingEndMark"> — </span>Several types of hypophysitis can enlarge the pituitary early in their course. Lymphocytic infiltration of the pituitary usually occurs in late pregnancy or the postpartum period, but can also be seen in women at other times and infrequently in men [<a href="#rid31">31</a>] and increasingly due to anti-cytotoxic T-lymphocyte antigen (CTLA)-4 treatment of malignancies [<a href="#rid32">32-34</a>]. It is characterized by headaches of an intensity out of proportion to the size of the lesion and hypopituitarism, in which adrenal insufficiency is unusually prominent. (See  <a class="medical medical_review" href="/d/html/6636.html" rel="external">"Causes of hypopituitarism", section on 'Hypophysitis'</a> and  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Hypophysitis'</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Sellar masses can present with neurologic symptoms, abnormalities related to under- or oversecretion of pituitary hormones, or as an incidental finding on radiologic examination performed for some other reason.</p><p class="headingAnchor" id="H19"><span class="h2">Visual defects</span><span class="headingEndMark"> — </span>Impaired vision is the most common symptom that leads a patient with a nonfunctioning adenoma, of which over 80 percent are gonadotroph adenomas, to seek medical attention [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas"</a>.)</p><p>Visual impairment is caused by suprasellar extension of the adenoma, leading to compression of the optic chiasm. The most common complaint is diminished vision in the temporal fields (bitemporal hemianopsia). One or both eyes may be affected and, if both, to variable degrees. Diminished visual acuity occurs when the optic chiasm is more severely compressed. Other patterns of visual loss can also occur. Thus, an intrasellar lesion should be suspected when there is any unexplained pattern of visual loss.</p><p>The onset of the visual deficit is usually so gradual that many patients do not seek ophthalmologic consultation for months or even years. Even at this time, the reason for the deficit may not be recognized, unless a visual field examination is performed, further delaying the diagnosis.</p><p class="headingAnchor" id="H20"><span class="h2">Other neurologic symptoms</span><span class="headingEndMark"> — </span>Other neurologic symptoms that may cause a patient with a sellar mass to seek medical attention include:</p><p class="bulletIndent1"><span class="glyph">●</span>Headaches, presumably caused by expansion of the sella. The quality of the headache is not specific.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diplopia, induced by oculomotor nerve compression resulting from lateral extension of the mass.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pituitary apoplexy induced by sudden hemorrhage into an adenoma, causing excruciating headache and diplopia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrospinal fluid rhinorrhea, caused by inferior extension of the mass, an extremely uncommon presentation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parinaud syndrome, a constellation of neuro-ophthalmologic findings (most often paralysis of upward conjugate gaze), that result from ectopic pinealomas. (See  <a class="medical medical_review" href="/d/html/6257.html" rel="external">"Ocular gaze disorders", section on 'Parinaud syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Hormone deficiencies</span><span class="headingEndMark"> — </span>At the time of initial presentation with a neurologic symptom, many patients with sellar masses, when carefully questioned, admit to symptoms of pituitary hormone deficiencies. However, these symptoms are not usually the reason that the patient seeks medical attention.</p><p>The most common pituitary hormone deficiencies are of gonadotropins, resulting in hypogonadism in both males and females.</p><p class="headingAnchor" id="H22"><span class="h1">EVALUATION OF A SELLAR MASS</span><span class="headingEndMark"> — </span>Sellar masses should be evaluated both radiologically and hormonally.</p><p class="headingAnchor" id="H23"><span class="h2">Radiologic procedures</span></p><p class="headingAnchor" id="H24"><span class="h3">MRI</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) with gadolinium is the single best imaging procedure for most sellar masses, and there is usually no need to perform any other imaging study. Certain MRI findings suggest a greater likelihood of some kinds of sellar masses than others [<a href="#rid36">36</a>]. As an example, a mass that is separate from the pituitary gland generally indicates that the mass is not a pituitary adenoma (<a class="graphic graphic_diagnosticimage graphicRef132029" href="/d/graphic/132029.html" rel="external">image 2</a>). However, no finding is usually pathognomonic of any one kind of mass (<a class="graphic graphic_diagnosticimage graphicRef132029" href="/d/graphic/132029.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef132030" href="/d/graphic/132030.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef132032" href="/d/graphic/132032.html" rel="external">image 4</a>). In situations in which the use of gadolinium is contraindicated, such as renal impairment or pregnancy, MRI without gadolinium may still be helpful.</p><p class="headingAnchor" id="H600539362"><span class="h4">Unenhanced image</span><span class="headingEndMark"> — </span>Normal pituitary tissue and most sellar lesions, pituitary adenomas, and other tumors, have a signal that is similar to or slightly greater in intensity than that of central nervous system (CNS) tissue. Cystic lesions, such as Rathke's cleft cysts, often have a low-intensity signal on T1-weighted images; however, craniopharyngiomas and even pituitary adenomas may be partially cystic and, therefore, have low-intensity signals. Furthermore, the signal intensity on T1-weighted images will be high if the protein or lipid concentration of the cyst fluid is high. On T2-weighted images, cystic lesions may have a high-intensity signal. Hemorrhage into the pituitary gland results in a high-intensity signal on both T1- and T2-weighted images.</p><p>Meningiomas typically have a brighter and more homogeneous signal than pituitary adenomas. They also have a suprasellar rather than a sellar epicenter and a dural-based attachment best seen after contrast enhancement [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H600539373"><span class="h4">Gadolinium-enhanced image</span><span class="headingEndMark"> — </span>Normal pituitary tissue takes up gadolinium to a greater degree than CNS tissue and therefore has a higher-intensity signal than the surrounding CNS. Both micro- and macroadenomas of the pituitary (as well as other sellar masses such as craniopharyngiomas and meningiomas) usually take up gadolinium to a lesser degree than the normal pituitary but more than the CNS. Therefore, the degree of gadolinium enhancement does not distinguish one kind of sellar mass from another. The postcontrast enhancement of meningiomas is usually homogeneous. If a sellar lesion can be seen as separate from the normal pituitary, whether on unenhanced or, more commonly, enhanced images, the lesion is usually not a pituitary adenoma.</p><p>Among patients with moderate to advanced renal failure (dialysis-dependent or estimated glomerular filtration rate [eGFR] less than 30 mL/min), the administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis. In such patients, gadolinium-based imaging should be avoided if possible. This issue, as well as the role of hemodialysis after the procedure if gadolinium-based imaging must be performed, is discussed separately. (See  <a class="medical medical_review" href="/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Approach to preventing nephrogenic systemic fibrosis'</a> and  <a class="medical medical_review" href="/d/html/1955.html" rel="external">"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease", section on 'Prevention'</a>.)</p><p class="headingAnchor" id="H3516484572"><span class="h3">MRI and CT</span><span class="headingEndMark"> — </span>Calcification in a craniopharyngioma or meningioma can be seen on imaging studies (<a class="graphic graphic_diagnosticimage graphicRef139625" href="/d/graphic/139625.html" rel="external">image 1</a>). (See  <a class="medical medical_review" href="/d/html/5210.html" rel="external">"Craniopharyngioma"</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Hormonal evaluation</span><span class="headingEndMark"> — </span>We recommend evaluation of hypothalamic-pituitary hormonal function whenever a sellar mass is encountered. Hormonal hypersecretion is caused only by pituitary adenomas. Consequently, the demonstration of hormonal hypersecretion identifies the sellar mass as a pituitary adenoma and also identifies the type of adenoma.</p><p>We therefore suggest measurements of serum prolactin (lactotroph adenomas), insulin-like growth factor-1 (IGF-1) (somatotroph adenomas), and plasma corticotropin (ACTH) and 24-hour urinary free cortisol (corticotroph adenomas).</p><p>Additional endocrine testing is needed when a gonadotroph or thyrotroph adenoma is suspected (luteinizing hormone [LH], follicle-stimulating hormone [FSH], total or free thyroxine [T4], and thyroid-stimulating hormone [TSH], respectively). Testing of alpha subunit is needed when either type of adenoma is suspected. (See  <a class="medical medical_review" href="/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas"</a> and  <a class="medical medical_review" href="/d/html/7842.html" rel="external">"TSH-secreting pituitary adenomas"</a>.)</p><p class="headingAnchor" id="H27"><span class="h3">Hormonal hypersecretion</span><span class="headingEndMark"> — </span>Hypersecretion, with the exception noted below, is caused only by pituitary adenomas. As a result, the demonstration of hormonal hypersecretion identifies both the sellar mass as a pituitary adenoma and the kind of adenoma:</p><p class="bulletIndent1"><span class="glyph">●</span>A serum prolactin concentration &gt;200 ng/mL generally identifies a lactotroph adenoma; values that are between 20 and 200 ng/mL could be due to a lactotroph adenoma or to any other sellar mass or medications. (See  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia", section on 'Serum prolactin concentrations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The best <strong>single</strong> test for the diagnosis of acromegaly is measurement of serum IGF-1. Among patients with equivocal values, serum growth hormone levels can be measured after an oral glucose load. (See  <a class="medical medical_review" href="/d/html/6635.html" rel="external">"Diagnosis of acromegaly"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated 24-hour urine cortisol excretion associated with a high-normal or high ACTH concentration usually indicates a corticotroph adenoma. (See  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gonadotroph adenomas can be identified by characteristic patterns of basal and thyrotropin-releasing hormone (TRH)-stimulated concentrations of gonadotropins and their subunits; these patterns differ somewhat in males and females. TRH is not currently available in the United States but is still available in many other countries. (See  <a class="medical medical_review" href="/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyrotroph adenomas are characterized by a clinically hyperthyroid patient who has a diffuse goiter and elevations in serum free T4 and triiodothyronine (T3) but an inappropriately normal or elevated serum TSH level. (See  <a class="medical medical_review" href="/d/html/7842.html" rel="external">"TSH-secreting pituitary adenomas"</a>.)</p><p></p><p class="headingAnchor" id="H28"><span class="h3">Hormonal hyposecretion</span><span class="headingEndMark"> — </span>In addition to testing for hormonal hypersecretion, the possibility of hormonal hyposecretion should be evaluated in all patients who have a sellar mass &gt;1 cm in order to identify and replace hormonal deficiencies (see  <a class="medical medical_review" href="/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a>). The presence of hormonal deficiencies, however, is not generally useful in the differential diagnosis of a sellar mass, since any mass can cause these deficiencies. One exception to this statement is that the spontaneous development of arginine vasopressin deficiency (AVP-D) indicates that the lesion affects the hypothalamus or the stalk and is therefore <strong>not a pituitary lesion</strong>. (See  <a class="medical medical_review" href="/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p class="headingAnchor" id="H29"><span class="h2">Pituitary incidentaloma</span><span class="headingEndMark"> — </span>The extent of the evaluation in a patient with an incidentally discovered intrasellar MRI signal abnormality depends upon its size. If it is larger than 1 cm, it should be evaluated as described above. If the mass is smaller than 1 cm, especially much smaller, and the patient has no clinical findings of pituitary dysfunction, we usually measure only the serum prolactin concentration, which, in one report, was much more cost effective than either measurement of multiple hormones or performance of follow-up MRIs at 6 and 12 months [<a href="#rid38">38</a>]. One exception may be the patient who is quite anxious about the presence of a small pituitary tumor. No evaluation for hormonal hyposecretion or visual abnormalities is necessary. (See  <a class="medical medical_review" href="/d/html/6642.html" rel="external">"Pituitary incidentalomas"</a>.)</p><p class="headingAnchor" id="H1999683521"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116762.html" rel="external">"Society guideline links: Pituitary tumors and hypopituitarism"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15891.html" rel="external">"Patient education: Prolactinoma (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/82820.html" rel="external">"Patient education: Pituitary adenoma (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2182.html" rel="external">"Patient education: High prolactin levels and prolactinomas (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2166.html" rel="external">"Patient education: Acromegaly (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/853.html" rel="external">"Patient education: Meningioma (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pituitary adenomas </strong>–<strong> </strong>Sellar masses usually present with neurologic symptoms, hormonal abnormalities, or as an incidental finding on magnetic resonance imaging (MRI). Pituitary adenomas are the most common cause of sellar masses, but other causes include:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Physiologic enlargement of the pituitary </strong>– Physiologic enlargement of the pituitary, most commonly during pregnancy, but also in primary hypothyroidism and primary hypogonadism. (See  <a class="medical medical_review" href="/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Benign tumors </strong>–<strong> </strong>Other benign tumors, such as craniopharyngioma and meningioma (<a class="graphic graphic_diagnosticimage graphicRef139625" href="/d/graphic/139625.html" rel="external">image 1</a>). (See  <a class="medical medical_review" href="/d/html/5210.html" rel="external">"Craniopharyngioma"</a> and  <a class="medical medical_review" href="/d/html/5220.html" rel="external">"Epidemiology, pathology, clinical features, and diagnosis of meningioma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Malignant tumors </strong>–<strong> </strong>Malignant tumors, both primary (germ cell tumor, chordoma, primary central nervous system [CNS] lymphoma) and metastatic (most commonly from breast and lung cancer). (See  <a class="medical medical_review" href="/d/html/5199.html" rel="external">"Intracranial germ cell tumors"</a> and  <a class="medical medical_review" href="/d/html/4693.html" rel="external">"Primary central nervous system lymphoma: Clinical features, diagnosis, and extent of disease evaluation"</a> and  <a class="medical medical_review" href="/d/html/5179.html" rel="external">"Chordoma and chondrosarcoma of the skull base"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypophysitis </strong>–<strong> </strong>Hypophysitis, especially lymphocytic (lymphocytic infiltration of the pituitary), occurs most commonly in postpartum women but can also be seen in women at other times, and rarely in men but increasingly due to anti-cytotoxic T-lymphocyte antigen (CTLA)-4 treatment of malignancies. (See <a class="local">'Hypophysitis'</a> above and  <a class="medical medical_review" href="/d/html/6636.html" rel="external">"Causes of hypopituitarism"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other </strong>–<strong> </strong>Sellar masses may also be due to a cyst, abscess, or arteriovenous fistula of the cavernous sinus. (See <a class="local">'Cysts'</a> above and <a class="local">'Abscess'</a> above and <a class="local">'Arteriovenous fistula of the cavernous sinus'</a> above.)</p><p></p><p class="bulletIndent1"><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MRI </strong>– We recommend MRI with gadolinium as the single best and usually only imaging procedure for most sellar masses. Certain MRI findings suggest a greater likelihood of some kinds of sellar masses than others. As an example, finding a mass that is separate from the pituitary gland generally indicates that the mass is not a pituitary adenoma.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Test for hormonal hypersecretion </strong>– We recommend evaluation of hypothalamic-pituitary hormonal function whenever a sellar mass is encountered. Hormonal hypersecretion is caused only by pituitary adenomas. Consequently, the demonstration of hormonal hypersecretion identifies the sellar mass as a pituitary adenoma and also identifies the type of adenoma. (See <a class="local">'Hormonal evaluation'</a> above.)</p><p></p><p class="bulletIndent2">Hormonal hyposecretion may be caused by any hypothalamic or pituitary lesion and therefore usually has no value in the differential diagnosis of a sellar mass. One exception to this statement is that the spontaneous development of arginine vasopressin deficiency (AVP-D) indicates that the lesion affects the hypothalamus or the stalk and is therefore <strong>not a pituitary lesion</strong>. (See  <a class="medical medical_review" href="/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Importance of size </strong>–<strong> </strong>The extent of the evaluation in a patient with an incidentally discovered intrasellar MRI signal abnormality (pituitary incidentaloma) depends upon its size. If it is larger than 1 cm, we recommend evaluating for hormonal hypersecretion and hyposecretion as described above (see <a class="local">'Hormonal evaluation'</a> above). If it is smaller than 10 mm and the patient has no clinical findings of pituitary dysfunction, we recommend measuring only the serum prolactin concentration. (See  <a class="medical medical_review" href="/d/html/6642.html" rel="external">"Pituitary incidentalomas"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gsponer J, De Tribolet N, Déruaz JP, et al. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine (Baltimore) 1999; 78:236.</a></li><li><a class="nounderline abstract_t">Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am 1999; 28:81.</a></li><li><a class="nounderline abstract_t">Saeger W, Lüdecke DK, Buchfelder M, et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007; 156:203.</a></li><li><a class="nounderline abstract_t">Alexander JM, Biller BM, Bikkal H, et al. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 1990; 86:336.</a></li><li><a class="nounderline abstract_t">Herman V, Fagin J, Gonsky R, et al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990; 71:1427.</a></li><li><a class="nounderline abstract_t">Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab 2010; 95:4268.</a></li><li><a class="nounderline abstract_t">Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72:377.</a></li><li><a class="nounderline abstract_t">Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998; 62:232.</a></li><li><a class="nounderline abstract_t">Crabtree JS, Scacheri PC, Ward JM, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A 2001; 98:1118.</a></li><li><a class="nounderline abstract_t">Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340:692.</a></li><li><a class="nounderline abstract_t">Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987; 330:566.</a></li><li><a class="nounderline abstract_t">Caimari F, Hernández-Ramírez LC, Dang MN, et al. Risk category system to identify pituitary adenoma patients with AIP mutations. J Med Genet 2018; 55:254.</a></li><li class="breakAll">Snyder PJ. Gonadotroph adenomas. In: Endocrinology, DeGroot LJ (Ed), WB Saunders, Philadelphia 2001.</li><li><a class="nounderline abstract_t">Bassetti M, Spada A, Arosio M, et al. Morphological studies on mixed growth hormone (GH)- and prolactin (PRL)-secreting human pituitary adenomas. Coexistence of GH and PRL in the same secretory granule. J Clin Endocrinol Metab 1986; 62:1093.</a></li><li><a class="nounderline abstract_t">Shimono T, Hatabu H, Kasagi K, et al. Rapid progression of pituitary hyperplasia in humans with primary hypothyroidism: demonstration with MR imaging. Radiology 1999; 213:383.</a></li><li><a class="nounderline abstract_t">Alkhani AM, Cusimano M, Kovacs K, et al. Cytology of pituitary thyrotroph hyperplasia in protracted primary hypothyroidism. Pituitary 1999; 1:291.</a></li><li><a class="nounderline abstract_t">Groff TR, Shulkin BL, Utiger RD, Talbert LM. Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism. Obstet Gynecol 1984; 63:86S.</a></li><li><a class="nounderline abstract_t">Samaan NA, Stepanas AV, Danziger J, Trujillo J. Reactive pituitary abnormalities in patients with Klinefelter's and Turner's syndromes. Arch Intern Med 1979; 139:198.</a></li><li><a class="nounderline abstract_t">Scheithauer BW, Moschopulos M, Kovacs K, et al. The pituitary in klinefelter syndrome. Endocr Pathol 2005; 16:133.</a></li><li><a class="nounderline abstract_t">Ezzat S, Asa SL, Stefaneanu L, et al. Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoid. J Clin Endocrinol Metab 1994; 78:555.</a></li><li><a class="nounderline abstract_t">Ragel BT, Couldwell WT. Pituitary carcinoma: a review of the literature. Neurosurg Focus 2004; 16:E7.</a></li><li><a class="nounderline abstract_t">Giustina A, Gola M, Doga M, Rosei EA. Clinical review 136: Primary lymphoma of the pituitary: an emerging clinical entity. J Clin Endocrinol Metab 2001; 86:4567.</a></li><li><a class="nounderline abstract_t">Fassett DR, Couldwell WT. Metastases to the pituitary gland. Neurosurg Focus 2004; 16:E8.</a></li><li><a class="nounderline abstract_t">Schubiger O, Haller D. Metastases to the pituitary--hypothalamic axis. An MR study of 7 symptomatic patients. Neuroradiology 1992; 34:131.</a></li><li><a class="nounderline abstract_t">Morita A, Meyer FB, Laws ER Jr. Symptomatic pituitary metastases. J Neurosurg 1998; 89:69.</a></li><li><a class="nounderline abstract_t">Trifanescu R, Ansorge O, Wass JA, et al. Rathke's cleft cysts. Clin Endocrinol (Oxf) 2012; 76:151.</a></li><li><a class="nounderline abstract_t">Culver SA, Grober Y, Ornan DA, et al. A Case for Conservative Management: Characterizing the Natural History of Radiographically Diagnosed Rathke Cleft Cysts. J Clin Endocrinol Metab 2015; 100:3943.</a></li><li><a class="nounderline abstract_t">Al-Holou WN, Terman S, Kilburg C, et al. Prevalence and natural history of arachnoid cysts in adults. J Neurosurg 2013; 118:222.</a></li><li><a class="nounderline abstract_t">Vates GE, Berger MS, Wilson CB. Diagnosis and management of pituitary abscess: a review of twenty-four cases. J Neurosurg 2001; 95:233.</a></li><li><a class="nounderline abstract_t">Sato N, Putman CM, Chaloupka JC, et al. Pituitary gland enlargement secondary to dural arteriovenous fistula in the cavernous sinus: appearance at MR imaging. Radiology 1997; 203:263.</a></li><li><a class="nounderline abstract_t">Thodou E, Asa SL, Kontogeorgos G, et al. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab 1995; 80:2302.</a></li><li><a class="nounderline abstract_t">Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13:29.</a></li><li><a class="nounderline abstract_t">Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30:825.</a></li><li><a class="nounderline abstract_t">Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009; 15:6267.</a></li><li class="breakAll">Snyder PJ. Gonadotroph adenomas. In: The Pituitary, 2nd, Melmed S (Ed), Blackwell Science Inc., Malden, MA 2002. p.575.</li><li class="breakAll">Pressman BD. Pituitary imaging. In: The Pituitary, 2nd, Melmed S (Ed), Blackwell Science Inc., Malden, MA 2002. p.663.</li><li><a class="nounderline abstract_t">Taylor SL, Barakos JA, Harsh GR 4th, Wilson CB. Magnetic resonance imaging of tuberculum sellae meningiomas: preventing preoperative misdiagnosis as pituitary macroadenoma. Neurosurgery 1992; 31:621.</a></li><li><a class="nounderline abstract_t">King JT Jr, Justice AC, Aron DC. Management of incidental pituitary microadenomas: a cost-effectiveness analysis. J Clin Endocrinol Metab 1997; 82:3625.</a></li></ol></div><div id="topicVersionRevision">Topic 6632 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10424206" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10207686" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Differential diagnosis of sellar masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287410" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1973174" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinically nonfunctioning pituitary tumors are monoclonal in origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1977759" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clonal origin of pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20534753" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Incidence of pituitary adenomas in Northern Finland in 1992-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19650784" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9463336" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Characterization of mutations in patients with multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158604" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2549426" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2825031" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29440248" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Risk category system to identify pituitary adenoma patients with AIP mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29440248" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk category system to identify pituitary adenoma patients with AIP mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3084531" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Morphological studies on mixed growth hormone (GH)- and prolactin (PRL)-secreting human pituitary adenomas. Coexistence of GH and PRL in the same secretory granule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10551216" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rapid progression of pituitary hyperplasia in humans with primary hypothyroidism: demonstration with MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11081211" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cytology of pituitary thyrotroph hyperplasia in protracted primary hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6700889" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/434974" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Reactive pituitary abnormalities in patients with Klinefelter's and Turner's syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16199898" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The pituitary in klinefelter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8126126" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15191336" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pituitary carcinoma: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11600505" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical review 136: Primary lymphoma of the pituitary: an emerging clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15191337" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Metastases to the pituitary gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1603311" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Metastases to the pituitary--hypothalamic axis. An MR study of 7 symptomatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9647174" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Symptomatic pituitary metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21951110" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rathke's cleft cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26305621" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A Case for Conservative Management: Characterizing the Natural History of Radiographically Diagnosed Rathke Cleft Cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23140149" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevalence and natural history of arachnoid cysts in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11780892" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diagnosis and management of pituitary abscess: a review of twenty-four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9122405" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pituitary gland enlargement secondary to dural arteriovenous fistula in the cavernous sinus: appearance at MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629223" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19639414" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18049334" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789309" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789309" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789309" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1407446" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Magnetic resonance imaging of tuberculum sellae meningiomas: preventing preoperative misdiagnosis as pituitary macroadenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360517" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Management of incidental pituitary microadenomas: a cost-effectiveness analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
